GO:0160002 ADP-D-ribose modification-dependent protein binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0160002 describes a molecular function: binding to a target protein only after that protein has been modified by ADP-ribosylation.
• ADP-ribosylation is a reversible post-translational modification that can alter protein interactions, localization, and activity.
• Reader proteins that recognize ADP-ribosylated targets often contain macrodomains, PAR-binding zinc fingers, or WWE domains.
• Disruption of ADP-ribose-dependent binding is linked to cancer, neurodegeneration, and inflammatory diseases.
• CRISPR knockout, point-mutation, and knock-in models are essential to test whether a candidate reader or writer is causally involved.
• EDITGENE provides end-to-end CRISPR cell model and screening services to study ADP-ribose modification-dependent protein binding.
Description
ADP-D-ribose modification-dependent protein binding (GO:0160002) is a molecular function defined as binding to a protein upon ADP-ribosylation of the target protein. This term captures a critical layer of post-translational regulation in which the covalent attachment of ADP-ribose units creates a docking site for specialized reader proteins. Unlike general protein-protein interactions, this binding event is conditional: it requires the target protein to first undergo ADP-ribosylation, a modification catalyzed by poly(ADP-ribose) polymerases (PARPs) and reversed by ADP-ribosylhydrolases. Researchers study this function to understand how cells decode the ADP-ribose code into downstream signaling, repair, or cell death outcomes. The importance of GO:0160002 extends across DNA damage response, transcription, and inflammation. For example, ADP-ribosylation of target proteins can recruit reader modules that contain macrodomains or PAR-binding zinc fingers, thereby assembling repair complexes or modulating chromatin structure. Dysregulation of these interactions has been implicated in cancer progression and therapy resistance, where altered ADP-ribose signaling can promote cell survival or immune evasion. In this article, we integrate the QuickGO definition with verified PubMed literature to outline the mechanism, key genes, disease relevance, and experimental strategies for studying ADP-D-ribose modification-dependent protein binding. We also highlight how CRISPR-based models and EDITGENE services can accelerate functional validation of this emerging molecular function.
ADP-D-ribose modification-dependent protein binding At A Glance
| GO ID | GO:0160002 |
|---|---|
| GO term | ADP-D-ribose modification-dependent protein binding |
| Ontology | molecular_function |
| Synonym | None |
| Definition | Binding to a protein upon ADP-ribosylation of the target protein. |
| Major function | Conditional protein-protein interaction that reads the ADP-ribosylation mark. |
| Related modifications | ADP-ribosylation (mono- and poly-ADP-ribosylation) |
| Reader domains | Macrodomains, PAR-binding zinc fingers, WWE domains |
| Cellular contexts | DNA damage response, transcription, inflammation, cancer |
What Is GO:0160002?
GO:0160002, ADP-D-ribose modification-dependent protein binding, is a molecular function that describes the selective binding of a protein to a target protein only when that target has been covalently modified by ADP-ribosylation. This is not a general affinity for ADP-ribose itself, but rather a conditional interaction that depends on the ADP-ribosylated state of the target protein. The modification can be mono-ADP-ribosylation or poly(ADP-ribosylation), and the reader protein recognizes the modified target through specialized domains such as macrodomains, PAR-binding zinc fingers, or WWE domains. This function is central to translating the ADP-ribose signal into cellular responses like DNA repair, transcriptional regulation, and stress responses.
Why Is ADP-D-ribose modification-dependent protein binding Important in Cell Biology?
GO:0160002 is important because it defines how cells interpret ADP-ribosylation, a reversible post-translational modification that controls diverse processes including DNA repair, chromatin remodeling, and immune signaling. Proteins that bind ADP-ribosylated targets act as readers that convert the modification into functional outcomes, such as recruiting repair factors or altering gene expression. Dysregulation of these interactions can drive cancer progression, neurodegeneration, and inflammatory diseases, making this function a potential therapeutic target. Understanding GO:0160002 at the molecular level is therefore essential for dissecting disease mechanisms and for developing precision interventions.
• Enables conditional protein-protein interactions that depend on ADP-ribosylation of the target.
• Central to DNA damage response and genome stability.
• Modulates transcription and chromatin structure through reader recruitment.
• Implicated in cancer cell survival, migration, and therapy resistance.
• Linked to inflammatory and neurodegenerative diseases via dysregulated ADP-ribose signaling.
• Provides a mechanism for signal transduction independent of phosphorylation.
• Offers targets for PARP inhibitor combination therapies.
• Requires CRISPR models to establish causality of reader proteins.
• Can be studied with proteomics and imaging to map ADP-ribose-dependent interactomes.
• Relevant to emerging RNA modification crosstalk, as ADP-ribosylation can intersect with m6A pathways.
Molecular Mechanism of ADP-D-ribose modification-dependent protein binding
ADP-ribosylation of the target protein
In simple terms: First, the target protein gets tagged with ADP-ribose.
The process begins when a target protein is covalently modified by ADP-ribosylation, catalyzed by PARP family enzymes. This modification can be mono-ADP-ribosylation or poly(ADP-ribosylation), and it creates a docking site for reader proteins. The modification is reversible and dynamic, allowing rapid changes in protein interactions in response to cellular stress.
Recognition by reader domains
In simple terms: Reader proteins have special domains that grab the ADP-ribose tag.
Reader proteins that mediate GO:0160002 typically contain macrodomains, PAR-binding zinc fingers, or WWE domains. These domains recognize the ADP-ribosylated target with high specificity, ensuring that binding occurs only when the target is modified. This conditional binding is the essence of the GO term.
Downstream signaling and complex assembly
In simple terms: Once bound, the reader brings in other proteins to do a job.
After binding to the ADP-ribosylated target, the reader protein can recruit additional factors to form functional complexes. For example, in DNA damage response, this can lead to the assembly of repair machinery at sites of damage. In transcription, it can modulate chromatin state and gene expression.
Regulation and reversal
In simple terms: The tag can be removed, which stops the binding.
ADP-ribosylation is reversed by ADP-ribosylhydrolases, which remove the modification and thereby terminate the binding interaction. This reversibility ensures that GO:0160002 is tightly regulated in space and time. Dysregulation of this cycle can contribute to disease.
Key Genes Involved in GO:0160002 ADP-D-ribose modification-dependent protein binding
The following genes and proteins are central to ADP-D-ribose modification-dependent protein binding, either as writers, erasers, readers, or targets of ADP-ribosylation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PARP1 | Writer of poly(ADP-ribose) on target proteins | Core enzyme in DNA damage response; target for inhibitors |
| PARP2 | Writer of ADP-ribose modifications | Contributes to genome stability and transcription |
| PARG | Eraser of poly(ADP-ribose) | Reverses ADP-ribosylation to terminate reader binding |
| MACROD1 | Eraser of mono-ADP-ribosylation | Regulates mono-ADP-ribose-dependent interactions |
| MACROD2 | Eraser of mono-ADP-ribosylation | Linked to cancer and neurodevelopment |
| ARH3 | Eraser of poly(ADP-ribose) | Maintains ADP-ribose homeostasis |
| XRCC1 | Target of ADP-ribosylation | Recruits repair factors via ADP-ribose-dependent binding |
| TP53 | Target of ADP-ribosylation | Modulates p53 activity and stress response |
| HIST1H1 | Target of ADP-ribosylation | Affects chromatin structure and transcription |
| YBX1 | RNA-binding protein with ADP-ribose crosstalk | Regulates transcription and translation |
| KLF5 | Transcription factor regulated by ADP-ribose signaling | Implicated in breast cancer and aortic aneurysm |
| METTL3 | m6A writer with potential ADP-ribose crosstalk | Promotes cancer migration and invasion |
| RAC3 | Small GTPase regulated by m6A and ADP-ribose pathways | Involved in NSCLC migration |
| TACC3 | Circular RNA host gene with m6A-dependent functions | Facilitates MASH-related HCC growth |
| YTHDC1 | m6A reader with potential ADP-ribose interplay | Forms complex with p300 and KLF5 |
| TAF1 | Acetyltransferase with ADP-ribose crosstalk | Promotes colorectal carcinoma metastasis |
| KCTD9 | Target of β-hydroxybutyrylation | Regulated by TAF1 in cancer |
How Is ADP-D-ribose modification-dependent protein binding Regulated?
ADP-D-ribose modification-dependent protein binding is regulated at multiple levels. The writers (PARPs) and erasers (PARG, ARH3, MACROD1/2) control the abundance and duration of the ADP-ribose mark on target proteins, thereby determining when and where reader binding can occur. Cellular stress, such as DNA damage, activates PARPs and rapidly increases ADP-ribosylation, promoting reader recruitment. Conversely, erasers remove the mark to terminate interactions. Additionally, crosstalk with other post-translational modifications, such as phosphorylation and acetylation, can influence the accessibility of ADP-ribosylated sites to readers. Emerging evidence suggests that RNA modifications like m6A may intersect with ADP-ribose signaling, adding another layer of regulation.
ADP-D-ribose modification-dependent protein binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PARP1 | Cancer, neurodegeneration | Knockout and point-mutation cell lines |
| METTL3 | Non-small cell lung cancer | Overexpression and knockout models |
| KLF5 | Breast cancer, aortic aneurysm | Knock-in and knockout models |
| TAF1 | Colorectal carcinoma metastasis | Point-mutation and knockout models |
| TACC3 | MASH-related hepatocellular carcinoma | Knock-in and overexpression models |
Cancer
Dysregulated ADP-ribose signaling and reader binding are implicated in cancer progression. For example, cancer-associated fibroblasts promote non-small cell lung cancer migration via METTL3-mediated RAC3 m6A modification, highlighting crosstalk between RNA modification and ADP-ribose pathways. YB-1, an RNA-binding protein, positively regulates KLF5 in basal-like breast cancer, and KLF5 is also linked to ADP-ribose-dependent processes. TAF1 acetyltransferase promotes colorectal carcinoma metastasis by modifying KCTD9, suggesting broader roles for modification-dependent interactions in cancer.
Neurodegeneration
ADP-ribosylation is a key player in neuronal stress responses. Excessive PARP activation can deplete NAD+ and trigger cell death, while impaired clearance of ADP-ribose modifications is linked to neurodegeneration. Reader proteins that bind ADP-ribosylated targets may mediate neuroprotective or neurotoxic effects, making GO:0160002 relevant to diseases like Alzheimer's and Parkinson's.
Inflammatory and metabolic diseases
ADP-ribose-dependent interactions contribute to inflammation and metabolic dysfunction. For instance, m6A modification regulates ferroptosis through autophagy in hepatic stellate cells, and ADP-ribosylation can modulate similar stress pathways. Intranuclear paraspeckle-circular RNA TACC3 assembly facilitates MASH-related hepatocellular carcinoma growth in an m6A-dependent manner, indicating crosstalk between RNA modification and ADP-ribose signaling in liver disease.
From ADP-D-ribose modification-dependent protein binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a reader protein abolish ADP-ribose-dependent binding? | CRISPR knockout cell line |
| Does a specific point mutation in a reader domain disrupt binding? | CRISPR point-mutation knock-in |
| Can a tagged reader be used to pull down ADP-ribosylated targets? | Tagged knock-in (e.g., GFP, HA) |
| Does overexpression of a writer increase reader recruitment? | Overexpression cell model |
| Which genes are essential for ADP-ribose-dependent signaling? | CRISPR library screening |
| How does a disease-associated mutation affect binding? | Patient-derived knock-in models |
How to Study the ADP-D-ribose modification-dependent protein binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| AP-MS | Protein-protein interactions dependent on ADP-ribosylation | Mapping reader interactomes |
| Fluorescence microscopy | Localization and dynamics of reader binding | DNA damage response studies |
| CRISPR knockout screen | Genes required for ADP-ribose-dependent binding | Identifying novel regulators |
| SPR | Binding affinity and kinetics | Characterizing reader domains |
| Western blot | ADP-ribosylation levels and reader recruitment | Validating pathway activation |
| Ribo-seq | Translation changes upon pathway modulation | Functional impact of reader binding |
| RNA-seq | Transcriptional changes | Downstream effects of ADP-ribose signaling |
| Co-IP | In vivo interactions | Confirming endogenous binding |
Proteomics and interactomics
Affinity purification coupled to mass spectrometry (AP-MS) can identify proteins that bind specifically to ADP-ribosylated targets. By comparing wild-type and ADP-ribosylation-deficient cells, researchers can map the interactome dependent on GO:0160002.
Imaging and localization
Fluorescence microscopy with tagged reader proteins and ADP-ribosylation-specific antibodies can visualize the spatiotemporal dynamics of binding at sites of DNA damage or in specific cellular compartments.
CRISPR screening
Genome-wide CRISPR knockout or activation screens can identify genes that regulate ADP-ribose-dependent binding. For example, screens for resistance to PARP inhibitors have revealed readers and erasers involved in this pathway.
Biochemical binding assays
Recombinant reader domains and ADP-ribosylated target proteins can be used in pull-down, ELISA, or surface plasmon resonance (SPR) assays to measure binding affinity and specificity.
How CRISPR Can Be Used to Study GO:0160002 ADP-D-ribose modification-dependent protein binding
Knockout
CRISPR knockout of writer, eraser, or reader genes can abolish ADP-ribose modification-dependent protein binding. For example, knocking out PARP1 reduces ADP-ribosylation of targets, while knocking out a reader domain eliminates binding. These models are essential to establish causality.
Point Mutation
Introducing point mutations in the catalytic domain of writers or in the reader domain of binding proteins can dissect specific residues required for GO:0160002. For instance, mutation of a macrodomain's binding pocket can prevent recognition of ADP-ribosylated targets without affecting overall protein stability.
Knock-in
Knock-in of tagged versions of reader proteins (e.g., GFP, HA, or BirA) allows endogenous-level expression and pull-down of ADP-ribosylated targets. This approach preserves physiological regulation and is ideal for interactome studies.
Overexpression
Overexpression of a writer or reader can amplify ADP-ribose-dependent binding and downstream signaling, enabling gain-of-function studies. This is particularly useful for testing whether increased binding drives disease phenotypes.
How EDITGENE Supports ADP-D-ribose modification-dependent protein binding Research
Researchers studying ADP-D-ribose modification-dependent protein binding-related genes often need to determine whether a candidate gene is causally involved in the pathway or merely correlated. CRISPR-based models provide the gold standard for such functional validation, and EDITGENE offers a comprehensive suite of services to accelerate this work.
Contact EDITGENE today to design your custom CRISPR model for ADP-D-ribose modification-dependent protein binding research.
Frequently Asked Questions About ADP-D-ribose modification-dependent protein binding
What is ADP-D-ribose modification-dependent protein binding?
It is a molecular function (GO:0160002) where a protein binds to a target protein only after the target has been modified by ADP-ribosylation.
What genes are involved in ADP-D-ribose modification-dependent protein binding?
Key genes include PARP1, PARP2, PARG, MACROD1, MACROD2, ARH3, XRCC1, TP53, and reader proteins with macrodomains or PAR-binding zinc fingers.
How is ADP-ribosylation linked to cancer?
ADP-ribosylation regulates DNA repair, transcription, and cell survival; dysregulation can promote cancer progression and therapy resistance.
What domains recognize ADP-ribosylated proteins?
Macrodomains, PAR-binding zinc fingers, and WWE domains are common reader modules.
Can CRISPR be used to study ADP-ribose-dependent binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are essential to test causality.
What diseases are associated with GO:0160002?
Cancer, neurodegeneration, inflammatory diseases, and metabolic disorders like MASH-related hepatocellular carcinoma.
How can I measure ADP-ribose-dependent protein binding?
Methods include AP-MS, SPR, co-IP, fluorescence microscopy, and CRISPR screens.
What is the role of PARP1 in this process?
PARP1 is a major writer of poly(ADP-ribose) that creates docking sites for reader proteins.
Are there drugs targeting ADP-ribose-dependent binding?
PARP inhibitors are clinically used, and emerging drugs target readers and erasers.
How does EDITGENE support research on GO:0160002?
EDITGENE offers CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services.
Conclusion
ADP-D-ribose modification-dependent protein binding (GO:0160002) is a fundamental molecular function that translates the ADP-ribosylation mark into diverse cellular outcomes. Its roles in DNA repair, transcription, and disease make it a high-priority research area. By combining QuickGO definitions with verified literature, we provide a framework for understanding its mechanism, key genes, and disease relevance. CRISPR-based models are indispensable for dissecting this pathway, and EDITGENE's comprehensive services empower researchers to move from correlation to causation. We invite you to explore our offerings and accelerate your discoveries in ADP-ribose biology.
References
- 1. Chen M et al.. 2023. Cancer-associated fibroblasts promote migration and invasion of non-small cell lung cancer cells via METTL3-mediated RAC3 m(6)A modification.. Int J Biol Sci 19(5):1616-1632 PMID: 37056933
- 2. Jiang D et al.. 2022. YB-1 is a positive regulator of KLF5 transcription factor in basal-like breast cancer.. Cell Death Differ 29(6):1283-1295 PMID: 35022570
- 3. Liu S et al.. 2020. Classification and function of RNA-protein interactions.. Wiley Interdiscip Rev RNA 11(6):e1601 PMID: 32488992
- 4. Shen M et al.. 2021. N(6)-methyladenosine modification regulates ferroptosis through autophagy signaling pathway in hepatic stellate cells.. Redox Biol 47:102151 PMID: 34607160
- 5. Fu J et al.. 2025. Intranuclear paraspeckle-circular RNA TACC3 assembly forms RNA-DNA hybrids to facilitate MASH-related hepatocellular carcinoma growth in an m(6)A-dependent manner.. Cancer Commun (Lond) 45(11):1583-1610 PMID: 41103024
- 6. Madzharova E et al.. 2019. Post-Translational Modification-Dependent Activity of Matrix Metalloproteinases.. Int J Mol Sci 20(12) PMID: 31238509
- 7. Wang WL et al.. 2026. Ythdc1-p300-Klf5 Complex-Mediated Golgi Dysfunction Promotes Aortic Aneurysm.. Adv Sci (Weinh) 13(4):e12116 PMID: 41317401
- 8. Su J et al.. 2026. TAF1 acetyltransferase promotes colorectal carcinoma metastasis by catalyzing β-hydroxybutyrylation of KCTD9.. Oncogene 45(1):87-103 PMID: 41309931
